Northern Trust Corp Bei Gene, Ltd. Transaction History

Northern Trust Corp

  • $600 Billion
  • Q3 2024

A detailed history of Northern Trust Corp transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Northern Trust Corp holds 12,374 shares of BGNE stock, worth $2.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,374
Previous 11,760 5.22%
Holding current value
$2.38 Million
Previous $1.68 Million 65.65%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
BUY
$143.93 - $224.51 $88,373 - $137,849
614 Added 5.22%
12,374 $2.78 Million
Q2 2024

Aug 14, 2024
BUY
$129.52 - $174.32 $87,944 - $118,363
679 Added 6.13%
11,760 $1.68 Million
Q1 2024

May 14, 2024
BUY
$141.8 - $181.47 $262,755 - $336,263
1,853 Added 20.08%
11,081 $1.73 Million
Q4 2023

Feb 13, 2024
BUY
$158.67 - $201.58 $83,143 - $105,627
524 Added 6.02%
9,228 $1.66 Million
Q3 2023

Nov 13, 2023
SELL
$179.87 - $225.13 $83,099 - $104,010
-462 Reduced 5.04%
8,704 $1.57 Million
Q2 2023

Aug 11, 2023
BUY
$178.3 - $266.78 $41,365 - $61,892
232 Added 2.6%
9,166 $1.63 Million
Q1 2023

May 15, 2023
SELL
$215.53 - $274.5 $5.5 Million - $7 Million
-25,502 Reduced 74.06%
8,934 $1.93 Million
Q4 2022

Feb 13, 2023
SELL
$125.51 - $229.3 $11 Million - $20 Million
-87,309 Reduced 71.71%
34,436 $7.57 Million
Q3 2022

Nov 14, 2022
BUY
$131.8 - $202.24 $884,509 - $1.36 Million
6,711 Added 5.83%
121,745 $16.4 Million
Q2 2022

Aug 12, 2022
BUY
$121.11 - $216.05 $996,856 - $1.78 Million
8,231 Added 7.71%
115,034 $18.6 Million
Q1 2022

May 13, 2022
SELL
$146.52 - $269.56 $1.09 Million - $2 Million
-7,421 Reduced 6.5%
106,803 $20.1 Million
Q4 2021

Feb 08, 2022
SELL
$248.56 - $389.34 $2.1 Million - $3.29 Million
-8,456 Reduced 6.89%
114,224 $30.9 Million
Q3 2021

Nov 15, 2021
SELL
$249.6 - $403.14 $19 Million - $30.8 Million
-76,320 Reduced 38.35%
122,680 $44.5 Million
Q2 2021

Aug 13, 2021
SELL
$292.75 - $367.01 $7.24 Million - $9.08 Million
-24,742 Reduced 11.06%
199,000 $68.3 Million
Q1 2021

May 12, 2021
SELL
$260.64 - $382.12 $786,611 - $1.15 Million
-3,018 Reduced 1.33%
223,742 $77.9 Million
Q4 2020

Feb 11, 2021
SELL
$221.31 - $316.61 $22.6 Million - $32.4 Million
-102,261 Reduced 31.08%
226,760 $58.6 Million
Q3 2020

Nov 16, 2020
BUY
$189.18 - $286.44 $3.29 Million - $4.98 Million
17,375 Added 5.58%
329,021 $94.2 Million
Q2 2020

Aug 14, 2020
BUY
$123.9 - $195.41 $40,391 - $63,703
326 Added 0.1%
311,646 $58.7 Million
Q1 2020

May 14, 2020
SELL
$121.84 - $173.19 $36.2 Million - $51.4 Million
-296,854 Reduced 48.81%
311,320 $38.3 Million
Q4 2019

Feb 14, 2020
BUY
$115.78 - $208.34 $1.08 Million - $1.93 Million
9,287 Added 1.55%
608,174 $101 Million
Q3 2019

Nov 13, 2019
BUY
$120.61 - $148.29 $479,183 - $589,156
3,973 Added 0.67%
598,887 $73.3 Million
Q2 2019

Aug 13, 2019
BUY
$113.99 - $146.86 $3.26 Million - $4.2 Million
28,569 Added 5.04%
594,914 $73.7 Million
Q1 2019

May 13, 2019
SELL
$122.82 - $151.83 $9,579 - $11,842
-78 Reduced 0.01%
566,345 $74.8 Million
Q4 2018

Feb 12, 2019
BUY
$107.01 - $175.15 $60.3 Million - $98.8 Million
563,865 Added 22043.2%
566,423 $79.4 Million
Q3 2018

Nov 14, 2018
BUY
$152.62 - $189.66 $47,006 - $58,415
308 Added 13.69%
2,558 $440,000
Q2 2018

Aug 14, 2018
BUY
$152.5 - $216.77 $69,082 - $98,196
453 Added 25.21%
2,250 $346,000
Q1 2018

May 09, 2018
BUY
$97.41 - $177.22 $175,045 - $318,464
1,797 New
1,797 $302,000

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $19.9B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email